Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome

This study has been completed.
Novo Nordisk A/S
Information provided by (Responsible Party):
Charlotte Hoeybye, Karolinska University Hospital Identifier:
First received: September 5, 2006
Last updated: September 11, 2016
Last verified: September 2016
The aim of this study is to study the effects of GH on body composition, lipid and glucose metabolism, physical performance and safety aspects in adults with PWS.The patients are randomized to either GH or placebo the first year of the study, subsequently followed by two years of GH treatment. the study is performed in Norway, Sweden and Denmark.

Condition Intervention
Prader-Willi Syndrome
Drug: Norditropin SimpleXx

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome

Resource links provided by NLM:

Further study details as provided by Charlotte Hoeybye, Karolinska University Hospital:

Primary Outcome Measures:
  • Changes in body composition (lean body mass and fat mass) measured by dual energy X-ray absorptiometry (DXA) [ Time Frame: 36 months ]

Secondary Outcome Measures:
  • Bone mineral density measured by DXA [ Time Frame: 36 months ]
  • Effects on forced expiratory volume (Peakflow) [ Time Frame: 36 months ]
  • Standard photography appearance according to visual analogue scale (VAS) [ Time Frame: 36 months ]
  • Effects on free and total IGF-I, IGF-binding protein (BP)-1 and 3 [ Time Frame: 36 months ]
  • Effects on lipids (fasting triglycerides(TG), total, HDL and LDL cholesterol) [ Time Frame: 36 months ]
  • Effects on body composition measured with bioimpedance [ Time Frame: 36 months ]
  • Effects on haemoglobin (Hb), leucocyte and thrombocyte counts, FSH, LH, estradiol, Testosterone, inhibin B, TSH and Thyroxine [ Time Frame: 36 months ]
  • Muscle and fat mass measured by abdominal and mid-femoral computerized tomography [ Time Frame: 36 months ]
  • Activity of daily living measured a.m. Guralnik [ Time Frame: 36 months ]
  • Quality of life estimated by questionnaires [ Time Frame: 36 months ]

Enrollment: 46
Study Start Date: April 2005
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Norditropin SimpleXx
0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
Drug: Norditropin SimpleXx
0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
Placebo Comparator: Placebo
Placebo for 12 months
Drug: Norditropin SimpleXx
0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.

Detailed Description:


Prader Willi syndrome (PWS) is a multi-symptomatic genetic disorder associated with abnormalities in the growth hormone (GH)-insulin-like-growth factor (IGF)-I axis and in the body composition. GH treatment is a registered indication in children with PWS, and improves growth rate and body composition. One pilot study in adult patients with clinical PWS has shown beneficial effects on body composition without simultaneous significant side effects. The aim of the present study is to evaluate the effects of GH treatment on body composition, muscle function and quality of life in PWS adults.


The study will be an investigator initiated and investigator sponsored multinational and multi-centre trial, including centres in Norway, Sweden and Denmark. Within each centre patients will be randomised (double blind) to one year treatment with daily injections of GH or placebo (efficacy), followed by a two year observation period on GH treatment (safety).


Twenty patients from each centre are included in the study. The patients need a genetically verified diagnosis and should be between 18 and 40 years old. Patients are excluded if GH treatment has been given within the last two years, if they have a malignancy or other serious diseases, in particular severe respiratory diseases.


Effect is evaluated primarily as changes in body composition, activity of daily living and quality of life.

SAFETY: Before starting in the study all patients will be examined for tonsillary hypertrophy and sleep apnoea. Oral Glucose Tolerance Tests will be performed regularly.


During the initial 4 weeks of the placebo-controlled study phase patients will be treated with sc injections of GH (Norditropin Simplexx) in the evening with doses of 0.3 mg/day respectively 0.4 mg/day if BW is below or above 100 kg. Thereafter doses will be increased to 0.6 mg/day (0.8 mg/day) and maintained fixed for 11 months. During the following 24 months open phase doses will be individually titrated.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Genetically verified PWS diagnosis (by methylation and FISH test.)
  • Between 18 and 50 years old
  • Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the treatment of the subject.)

Exclusion Criteria:

  • Known or suspected allergy to GH preparation.
  • Previous participation in this trial.
  • GH treatment within the last 1 years
  • Malignancy or other serious diseases (ex severe cardiovascular diseases, severe infections)
  • Sexhormone treatment initiated within the last year
  • Pregnancy
  • Untreated respiratory impairment, untreated sleep apnoea or untreated respiratory infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00372125

Center for rare Diseases, Department of Pediatrics, Skejby University Hospital
Aarhus N, Denmark, 8200
Endokrinologisk seksjon, Med Avd, Rikshospitalet
Oslo, Norway
Department of Endocrinology and Diabetology, Karolinska Hospital
Stockholm, Sweden, 171 76
Sponsors and Collaborators
Karolinska University Hospital
Novo Nordisk A/S
Principal Investigator: Charlotte Hoybye, Dr. Department of Endocrinology and Diabetology, Karolinska Hospital
Study Chair: Jens S Christiansen, Professor Århus University Hospital, Denmark
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Charlotte Hoeybye, MD, PhD, Karolinska University Hospital Identifier: NCT00372125     History of Changes
Other Study ID Numbers: CH1234
Study First Received: September 5, 2006
Last Updated: September 11, 2016

Keywords provided by Charlotte Hoeybye, Karolinska University Hospital:
Prader-Willi syndrome
Growth hormone
Body composition

Additional relevant MeSH terms:
Prader-Willi Syndrome
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Nutrition Disorders
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017